In the Race for Alternative MOA Biologic in Crohn’s Disease, Takeda’s Entyvio Maintains the Lead, but Janssen’s Stelara is Gaining Fast
Not only has Stelara’s user-base substantially increased since Q1, but US gastroenterologists (n=103) are projecting significant gains for the IL-12/23 inhibitor over the next six months. Download Report Overview EXTON, Pa., June 27, 2017 /PRNewswire/ — Spherix Global Insights has just released the second quarter results of an independent survey regarding the evolving practice patterns […]
Novartis’ Cosentyx and Eli Lilly’s Taltz Bring Disruption to the Psoriasis Market as IL-17 Share Increases Dramatically
While AbbVie’s Humira and Amgen’s Enbrel have borne the brunt of the IL-17 assault, Janssen’s Stelara has been buffered thus far. However, future projections indicate a flattening of the brand and further penetration of the IL-17 class, according to a new report by Spherix Global Insights Download Report Overview EXTON, Pa., June 21, 2017 /PRNewswire/ […]
Janssen’s Stelara overtakes Takeda’s Entyvio as the leading alternative MOA in Crohn’s Disease, but pressure is on to maximize IBD value in advance of pipeline drugs from Celgene (mongersen, ozanimod), Roche/Genentech (etrolizumab) and Pfizer (Xeljanz)
According to RealWorld Dynamix: Biologic Switching in IBD, an annual patient chart analysis conducted by Spherix Global Insights, biologic use in IBD is becoming increasingly dynamic, with switching rates up significantly in both Ulcerative Colitis (UC) and Crohn’s Disease (CD) compared to 2016. Furthermore, switching patterns have changed dramatically with the recent introduction of Stelara. […]
Dupixent Delivers… and Sanofi-Regeneron Ushers in a New Era of Atopic Dermatitis (AD) Treatment
According to Spherix Global Insights, at just one month post-launch, nearly one-third of surveyed dermatologists (n=101) have prescribed Dupixent, although for some a burdensome reimbursement process is slowing the time from prescription to fulfillment. Download Report Overview EXTON, Pa., May 17, 2017 /PRNewswire/ — According to the latest RealTime Dynamix™: Atopic Dermatitis report, just one […]
Novartis’ Cosentyx Takes the Wind Out of Stelara’s Sails in Psoriatic Arthritis Market
New findings in a recent study by Spherix Global Insights, RealWorld Dynamix™: Biologic and Otezla Switching in PsA, indicate an increased rate of switching to the brand and strong momentum for Cosentyx compared to previous results collected in November 2015 Download Report Overview EXTON, Pa., May 16, 2017 /PRNewswire/ — A recent patient chart analysis […]
Roche’s Ocrevus: Penetrating Beyond Progressive MS
Recent analysis of over 2,000 patient charts indicates Ocrevus will present a challenge to other disease-modifying therapies (DMTs) in the RRMS segment as well as the PPMS segment, according to new data released by Spherix Global Insights. Download Report Overview: Multiple Sclerosis Download Report Overview: DMT New Starts in MS EXTON, Pa., May 12, 2017 […]
Keryx’s Auryxia and Vifor-FMC’s Velphoro Slowly Gaining Share in the Phosphate Binder Market While Big Shifts in CKD-MBD Loom With the Pending Introduction of Amgen’s Parsabiv
Over 300 US nephrologists and renal dietitians (RD) describe future practice pattern changes in most recent quarterly update by Spherix Global Insights. Download Report Overview EXTON, Pa., May 10, 2017 /PRNewswire/ — In a market long dominated by Sanofi-Genzyme’s Renvela, there are signs that the newer non-calcium, iron-based binders (Keryx’s Auryxia and Vifor-FMC’s Velphoro) are […]
EU Rheumatoid Arthritis Landscape Poised for Big Changes as Rheumatologists Plan for the Adoption of Eli Lilly/Incyte’s Olumiant, Pfizer’s Xeljanz, and Regeneron/Sanofi’s Kevzara
With the recent approval of two new JAK inhibitors and the imminent introduction of additional IL-6 inhibitors, EU rheumatologists anticipate substantial practice shifts in RA management. Download Report Overview EXTON, Pa., May 4, 2017 /PRNewswire/ — Spherix Global Insights recently released data collected from 257 rheumatologists in France, Germany, Italy, Spain and the UK, revealing […]
Preference, Persistency and Positioning for Lilly’s Taltz in Psoriasis Highlight a Potential Challenge Ahead for Novartis’ Cosentyx in PsO and Psoriatic Arthritis
Spherix Global Insights has released the results of two independent surveys of dermatologists (n=100) and rheumatologists (n=100) about the evolving practice patterns in the management of psoriasis (PsO) and psoriatic arthritis (PsA). Download Report Overview: Psoriasis Download Report Overview: Psoriatic Arthritis CAMBRIDGE, MASSACHUSETTS (PRWEB) APRIL 17, 2017 Despite positive perceptions, and brand expansion from the […]
RealTime Dynamix™: Atopic Dermatitis US Q2
Atopic dermatitis, the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. Until […]